Bausch Health Companies Inc. Amortization of Debt Issuance Costs
Bausch Health Companies Inc. (BHC) reported Amortization of Debt Issuance Costs of $2.50 million for the 3-month period ending 2012-03-31, per its 10-Q filed 2012-05-04.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AmortizationOfFinancingCosts · last filed 2012-05-04
- Bausch Health Companies Inc. amortization of debt issuance costs for the quarter ending 2012-03-31 was $2.50M, a 93.34% increase year-over-year.
- Bausch Health Companies Inc. amortization of debt issuance costs for the quarter ending 2011-12-31 was $6.08M, a 655.65% increase year-over-year.
- Bausch Health Companies Inc. amortization of debt issuance costs for the quarter ending 2011-09-30 was $10.77M, a 57.11% increase year-over-year.
- Bausch Health Companies Inc. amortization of debt issuance costs for the quarter ending 2011-06-30 was $469.00K, a 64.79% decline year-over-year.
- Bausch Health Companies Inc. amortization of debt issuance costs for fiscal 2011 was $18.61M, a 80.65% increase from fiscal 2010.
- Bausch Health Companies Inc. amortization of debt issuance costs for fiscal 2010 was $10.30M, a 184.61% increase from fiscal 2009.
- Bausch Health Companies Inc. amortization of debt issuance costs for fiscal 2009 was $3.62M, a 596.15% increase from fiscal 2008.
- Bausch Health Companies Inc. amortization of debt issuance costs for fiscal 2008 was $520.00K.
| Period end | Amortization of Debt Issuance Costs 3 month | Amortization of Debt Issuance Costs 6 month | Amortization of Debt Issuance Costs 9 month | Amortization of Debt Issuance Costs 12 month |
|---|---|---|---|---|
| 2012-03-31 | $2.50M 10-Q · filed 2012-05-04 | $8.58M derived: sum of 2 quarters · filed 2012-05-04 | $19.35M derived: sum of 3 quarters · filed 2012-05-04 | $19.82M derived: sum of 4 quarters · filed 2012-05-04 |
| 2011-12-31 | $6.08M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-29 | $16.85M derived: sum of 2 quarters · filed 2012-02-29 | $17.32M derived: sum of 3 quarters · filed 2012-02-29 | $18.61M 10-K · filed 2012-02-29 |
| 2011-09-30 | $10.77M 10-Q · filed 2011-11-04 | $11.24M derived: sum of 2 quarters · filed 2011-11-04 | $12.53M 10-Q · filed 2011-11-04 | $13.33M derived: sum of 4 quarters · filed 2012-05-04 |
| 2011-06-30 | $469.00K 10-Q · filed 2011-08-08 | $1.76M 10-Q · filed 2011-08-08 | $2.57M derived: sum of 3 quarters · filed 2012-05-04 | $9.42M derived: sum of 4 quarters · filed 2012-05-04 |
| 2011-03-31 | $1.29M 10-Q · filed 2012-05-04 | $2.10M derived: sum of 2 quarters · filed 2012-05-04 | $8.95M derived: sum of 3 quarters · filed 2012-05-04 | $10.28M derived: sum of 4 quarters · filed 2012-05-04 |
| 2010-12-31 | $805.00K derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-29 | $7.66M derived: sum of 2 quarters · filed 2012-02-29 | $8.99M derived: sum of 3 quarters · filed 2012-02-29 | $10.30M 10-K · filed 2012-02-29 |
| 2010-09-30 | $6.85M 10-Q · filed 2011-11-04 | $8.19M derived: sum of 2 quarters · filed 2011-11-04 | $9.50M 10-Q · filed 2011-11-04 | $10.79M derived: sum of 4 quarters · filed 2012-02-29 |
| 2010-06-30 | $1.33M 10-Q · filed 2011-08-08 | $2.64M 10-Q · filed 2011-08-08 | $3.94M derived: sum of 3 quarters · filed 2012-02-29 | $5.17M derived: sum of 4 quarters · filed 2012-02-29 |
| 2010-03-31 | $1.31M 10-Q · filed 2011-05-10 | $2.61M derived: sum of 2 quarters · filed 2012-02-29 | $3.83M derived: sum of 3 quarters · filed 2012-02-29 | $4.80M derived: sum of 4 quarters · filed 2012-02-29 |
| 2009-12-31 | $1.29M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-29 | $2.52M derived: sum of 2 quarters · filed 2012-02-29 | $3.49M derived: sum of 3 quarters · filed 2012-02-29 | $3.62M 10-K · filed 2012-02-29 |
| 2009-09-30 | $1.23M 10-Q · filed 2010-11-05 | $2.20M derived: sum of 2 quarters · filed 2010-11-05 | $2.33M 10-Q · filed 2010-11-05 | |
| 2009-06-30 | $968.00K 10-Q · filed 2010-08-06 | $1.10M 10-Q · filed 2010-08-06 | ||
| 2008-12-31 | $520.00K 10-K · filed 2011-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 |